A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab

An 81‐year‐old man initially underwent right hepatic lobectomy for liver cancer and was pathologically diagnosed with combined hepatocellular and cholangiocarcinoma (CHC). At 13 months after resection, multiple lymph node metastases were observed. We started atezolizumab plus bevacizumab (Atez/Bev),...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Naoto, Hatanaka, Takeshi, Nakano, Sachi, Hazama, Yoichi, Yoshida, Sachiko, Hachisu, Yoko, Tanaka, Yoshiki, Yoshinaga, Teruo, Kashiwabara, Kenji, Kubo, Norio, Hosouchi, Yasuo, Tojima, Hiroki, Kakizaki, Satoru, Uraoka, Toshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309740/
https://www.ncbi.nlm.nih.gov/pubmed/35898742
http://dx.doi.org/10.1002/ccr3.6129
_version_ 1784753234822299648
author Saito, Naoto
Hatanaka, Takeshi
Nakano, Sachi
Hazama, Yoichi
Yoshida, Sachiko
Hachisu, Yoko
Tanaka, Yoshiki
Yoshinaga, Teruo
Kashiwabara, Kenji
Kubo, Norio
Hosouchi, Yasuo
Tojima, Hiroki
Kakizaki, Satoru
Uraoka, Toshio
author_facet Saito, Naoto
Hatanaka, Takeshi
Nakano, Sachi
Hazama, Yoichi
Yoshida, Sachiko
Hachisu, Yoko
Tanaka, Yoshiki
Yoshinaga, Teruo
Kashiwabara, Kenji
Kubo, Norio
Hosouchi, Yasuo
Tojima, Hiroki
Kakizaki, Satoru
Uraoka, Toshio
author_sort Saito, Naoto
collection PubMed
description An 81‐year‐old man initially underwent right hepatic lobectomy for liver cancer and was pathologically diagnosed with combined hepatocellular and cholangiocarcinoma (CHC). At 13 months after resection, multiple lymph node metastases were observed. We started atezolizumab plus bevacizumab (Atez/Bev), achieving a 7.5‐month progression‐free survival. Atez/Bev might exhibit efficacy for CHC patients.
format Online
Article
Text
id pubmed-9309740
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93097402022-07-26 A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab Saito, Naoto Hatanaka, Takeshi Nakano, Sachi Hazama, Yoichi Yoshida, Sachiko Hachisu, Yoko Tanaka, Yoshiki Yoshinaga, Teruo Kashiwabara, Kenji Kubo, Norio Hosouchi, Yasuo Tojima, Hiroki Kakizaki, Satoru Uraoka, Toshio Clin Case Rep Case Report An 81‐year‐old man initially underwent right hepatic lobectomy for liver cancer and was pathologically diagnosed with combined hepatocellular and cholangiocarcinoma (CHC). At 13 months after resection, multiple lymph node metastases were observed. We started atezolizumab plus bevacizumab (Atez/Bev), achieving a 7.5‐month progression‐free survival. Atez/Bev might exhibit efficacy for CHC patients. John Wiley and Sons Inc. 2022-07-25 /pmc/articles/PMC9309740/ /pubmed/35898742 http://dx.doi.org/10.1002/ccr3.6129 Text en © 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Saito, Naoto
Hatanaka, Takeshi
Nakano, Sachi
Hazama, Yoichi
Yoshida, Sachiko
Hachisu, Yoko
Tanaka, Yoshiki
Yoshinaga, Teruo
Kashiwabara, Kenji
Kubo, Norio
Hosouchi, Yasuo
Tojima, Hiroki
Kakizaki, Satoru
Uraoka, Toshio
A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
title A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
title_full A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
title_fullStr A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
title_full_unstemmed A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
title_short A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
title_sort case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309740/
https://www.ncbi.nlm.nih.gov/pubmed/35898742
http://dx.doi.org/10.1002/ccr3.6129
work_keys_str_mv AT saitonaoto acaseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT hatanakatakeshi acaseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT nakanosachi acaseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT hazamayoichi acaseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT yoshidasachiko acaseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT hachisuyoko acaseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT tanakayoshiki acaseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT yoshinagateruo acaseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT kashiwabarakenji acaseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT kubonorio acaseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT hosouchiyasuo acaseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT tojimahiroki acaseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT kakizakisatoru acaseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT uraokatoshio acaseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT saitonaoto caseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT hatanakatakeshi caseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT nakanosachi caseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT hazamayoichi caseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT yoshidasachiko caseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT hachisuyoko caseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT tanakayoshiki caseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT yoshinagateruo caseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT kashiwabarakenji caseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT kubonorio caseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT hosouchiyasuo caseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT tojimahiroki caseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT kakizakisatoru caseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab
AT uraokatoshio caseofunresectablecombinedhepatocellularandcholangiocarcinomatreatedwithatezolizumabplusbevacizumab

Ejemplares similares